[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO Treatment - DrugsIntervention group: The study group in addition to the drugs used in the treatment of COVID-19 (approved by the National Committee), is treated with oral Bosentan 62.5 mg twice a day for 30 days. Patients will be followed for 30 days for recovery or discharge, duration of mechanical ventilation dependency, length of hospital stay, mortality, and thromboembolic events.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO PlaceboControl group: The control group, in addition to the drugs used in the treatment of COVID-19 (approved by the National Committee), receive a placebo twice a day for 30 days. Patients will be followed for 30 days for recovery or discharge, duration of mechanical ventilation dependency, length of hospital stay, mortality, and thromboembolic events.", "treatment_type": "TODO", "pharmacological_treatment": "Placebo"}]

[{"arm_notes": "", "treatment_id": 2095, "treatment_name": "Bosentan", "treatment_type": "Cardiovascular agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]